(redirected from Lennox-Gastaut syndrome)
Also found in: Medical, Wikipedia.
Category filter:
LGSLight Green Seal (currency)
LGSLocal Gun Store
LGSLoughborough Grammar School (UK)
LGSLane Guard System
LGSLennox-Gastaut Syndrome
LGSLead Generation Specialist (communications position)
LGSLeaky Gut Syndrome
LGSLangley Grammar School (UK)
LGSLaser Guide Star
LGSLauriston Girls' School (Australia)
LGSLight Gauge Steel (steel frame construction system)
LGSLodi Gas Storage (Houston, TX)
LGSLanger-Giedion Syndrome
LGSLouisiana Geological Society (est. 1934)
LGSLaw, Gender and Sexuality
LGSLooking Glass Studios (game development company)
LGSLocal Game Store (roleplaying)
LGSLow Growth Scenario (economic model)
LGSLoan Guarantee Scheme (UK)
LGSLight Gasoline Splitter (petroleum industry)
LGSLarge Group Speech (various organizations)
LGSLa Garde Suisse (French: Swiss Guard)
LGSLow-Gravity Solids (oilfield)
LGSLicensed Gun Store
LGSLandsat-7 Ground Station
LGSLegislation et Gestion Scolaire
LGSLets Get Serious
LGSLouisiana Geriatrics Society
LGSLayered Gene Scanning
LGSLadybird Grammar School (Karachi, Pakistan)
LGSLocation Grouping System
LGSLocation-Guided Steiner Tree
LGSLunar Geodetic Scout
LGSLow-Grade Stockpile (mining)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
My cousin, Lili, is 6 years old and has Lennox-Gastaut syndrome, which causes her to be unable to talk and have trouble with motor skills, such as walking.
Because the drug does not affect cognition as much as other add-on therapy options, it may be especially appropriate for patients with Lennox-Gastaut syndrome, Samuel Koszer, M.D., said in a poster presented at the meeting.
The report provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
A 12-week double-blind comparative study of rufinamide versus placebo as an adjunctive therapy to other antiepileptic drugs (AEDs) was conducted in 59 patients with Lennox-Gastaut syndrome (LGS) aged between 4 and 30 years old.
The drug is approved as adjunctive therapy for children with partial or generalized seizures associated with Lennox-Gastaut syndrome.
Food and Drug Administration to treat patients two years and older with Dravet Syndrome and Lennox-Gastaut Syndrome, two rare forms of epilepsy that emerge during childhood.
M2 EQUITYBITES-September 3, 2018-Aquestive Therapeutics Inc wins US FDA's tentative approval for Sympazan (clobazam) oral film for treating Lennox-Gastaut Syndrome
M2 PHARMA-September 3, 2018-Aquestive Therapeutics Inc wins US FDA's tentative approval for Sympazan (clobazam) oral film for treating Lennox-Gastaut Syndrome
announced today that it has received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour and Welfare (MHLW) for antiepileptic agent Inovelon(R) (rufinamide), approving the drug as an adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of Lennox-Gastaut syndrome (LGS), a rare disorder.
25 May 2010 - Danish pharma major H Lundbeck A/S (CPH: LUN) unveiled today positive data from the pivotal phase III clinical study with clobazam for the treatment of Lennox-Gastaut syndrome (LGS) and expects to file for approval of the drug in the USA by year-end 2010.
Topiramate is currently approved only as add-on therapy for treatment of partial-onset seizures, primary generalized tonicclonic seizures, or Lennox-Gastaut syndrome in adults and in children 2-16 years old.